KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Common Equity: 2010-2025

Historic Common Equity for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $582.5 million.

  • Emergent BioSolutions' Common Equity rose 14.58% to $582.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $582.5 million, marking a year-over-year increase of 14.58%. This contributed to the annual value of $482.8 million for FY2024, which is 25.64% down from last year.
  • Emergent BioSolutions' Common Equity amounted to $582.5 million in Q3 2025, which was up 8.63% from $536.2 million recorded in Q2 2025.
  • Emergent BioSolutions' Common Equity's 5-year high stood at $1.6 billion during Q4 2021, with a 5-year trough of $386.3 million in Q2 2024.
  • For the 3-year period, Emergent BioSolutions' Common Equity averaged around $656.5 million, with its median value being $582.5 million (2025).
  • As far as peak fluctuations go, Emergent BioSolutions' Common Equity skyrocketed by 41.68% in 2021, and later slumped by 59.66% in 2024.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Common Equity stood at $1.6 billion in 2021, then fell by 13.89% to $1.4 billion in 2022, then slumped by 53.21% to $649.3 million in 2023, then dropped by 25.64% to $482.8 million in 2024, then rose by 14.58% to $582.5 million in 2025.
  • Its last three reported values are $582.5 million in Q3 2025, $536.2 million for Q2 2025, and $552.7 million during Q1 2025.